Antiphospholipid Antibody Profile Stability Over Time : Prospective Results From the APS ACTION Clinical Database and Repository
Copyright © 2021 by the Journal of Rheumatology..
OBJECTIVE: The APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. Our secondary objectives were to determine (1) whether baseline characteristics differ between patients with stable and unstable aPL profiles, and (2) predictors of unstable aPL profiles over time.
METHODS: A clinically meaningful aPL profile was defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-β2 glycoprotein-I (anti-β2-GPI) IgG/M ≥ 40 U. Stable aPL profile was defined as a clinically meaningful aPL profile in at least two-thirds of follow-up measurements. Generalized linear mixed models with logit link were used for primary objective analysis.
RESULTS: Of 472 patients with clinically meaningful aPL profile at baseline (median follow-up 5.1 yrs), 366/472 (78%) patients had stable aPL profiles over time, 54 (11%) unstable, and 52 (11%) inconclusive. Time did not significantly affect odds of maintaining a clinically meaningful aPL profile at follow-up in univariate (P = 0.906) and multivariable analysis (P = 0.790). Baseline triple aPL positivity decreased (OR 0.25, 95% CI 0.10-0.64, P = 0.004) and isolated LAC test positivity increased (OR 3.3, 95% CI 1.53-7.13, P = 0.002) the odds of an unstable aPL profile over time.
CONCLUSION: Approximately 80% of our international cohort patients with clinically meaningful aPL profiles at baseline remain stable at a median follow-up of 5 years; triple aPL-positivity increase the odds of a stable aPL profile. These results will guide future validation studies of stored blood samples through APS ACTION Core Laboratories.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
The Journal of rheumatology - 48(2021), 4 vom: 22. Apr., Seite 541-547 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gkrouzman, Elena [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 20.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3899/jrheum.200513 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318256398 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318256398 | ||
| 003 | DE-627 | ||
| 005 | 20231227134651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.200513 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1233.xml |
| 035 | |a (DE-627)NLM318256398 | ||
| 035 | |a (NLM)33259328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gkrouzman, Elena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiphospholipid Antibody Profile Stability Over Time |b Prospective Results From the APS ACTION Clinical Database and Repository |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 20.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by the Journal of Rheumatology. | ||
| 520 | |a OBJECTIVE: The APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients. Our primary objective was to determine whether clinically meaningful aPL profiles at baseline remain stable over time. Our secondary objectives were to determine (1) whether baseline characteristics differ between patients with stable and unstable aPL profiles, and (2) predictors of unstable aPL profiles over time | ||
| 520 | |a METHODS: A clinically meaningful aPL profile was defined as positive lupus anticoagulant (LAC) test and/or anticardiolipin (aCL)/anti-β2 glycoprotein-I (anti-β2-GPI) IgG/M ≥ 40 U. Stable aPL profile was defined as a clinically meaningful aPL profile in at least two-thirds of follow-up measurements. Generalized linear mixed models with logit link were used for primary objective analysis | ||
| 520 | |a RESULTS: Of 472 patients with clinically meaningful aPL profile at baseline (median follow-up 5.1 yrs), 366/472 (78%) patients had stable aPL profiles over time, 54 (11%) unstable, and 52 (11%) inconclusive. Time did not significantly affect odds of maintaining a clinically meaningful aPL profile at follow-up in univariate (P = 0.906) and multivariable analysis (P = 0.790). Baseline triple aPL positivity decreased (OR 0.25, 95% CI 0.10-0.64, P = 0.004) and isolated LAC test positivity increased (OR 3.3, 95% CI 1.53-7.13, P = 0.002) the odds of an unstable aPL profile over time | ||
| 520 | |a CONCLUSION: Approximately 80% of our international cohort patients with clinically meaningful aPL profiles at baseline remain stable at a median follow-up of 5 years; triple aPL-positivity increase the odds of a stable aPL profile. These results will guide future validation studies of stored blood samples through APS ACTION Core Laboratories | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a anticardiolipin antibodies | |
| 650 | 4 | |a antiphospholipid antibodies | |
| 650 | 4 | |a antiphospholipid syndrome | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 650 | 7 | |a beta 2-Glycoprotein I |2 NLM | |
| 700 | 1 | |a Sevim, Ecem |e verfasserin |4 aut | |
| 700 | 1 | |a Finik, Jackie |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, Danieli |e verfasserin |4 aut | |
| 700 | 1 | |a Pengo, Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Sciascia, Savino |e verfasserin |4 aut | |
| 700 | 1 | |a Tektonidou, Maria G |e verfasserin |4 aut | |
| 700 | 1 | |a Ugarte, Amaia |e verfasserin |4 aut | |
| 700 | 1 | |a Chighizola, Cecilia B |e verfasserin |4 aut | |
| 700 | 1 | |a Belmont, H Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Pedrera, Chary |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Lanlan |e verfasserin |4 aut | |
| 700 | 1 | |a Fortin, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Efthymiou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a de Jesus, Guilherme Ramires |e verfasserin |4 aut | |
| 700 | 1 | |a Branch, D Ware |e verfasserin |4 aut | |
| 700 | 1 | |a Nalli, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Petri, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Cervera, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Jason S |e verfasserin |4 aut | |
| 700 | 1 | |a Atsumi, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Willis, Rohan |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolaccini, Maria Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Rand, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Erkan, Doruk |e verfasserin |4 aut | |
| 700 | 0 | |a APS ACTION+ |e verfasserin |4 aut | |
| 700 | 1 | |a Pons-Estel, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Giannakopoulos, Bill |e investigator |4 oth | |
| 700 | 1 | |a Krilis, Steve |e investigator |4 oth | |
| 700 | 1 | |a de Jesus, Guilherme |e investigator |4 oth | |
| 700 | 1 | |a Levy, Roger |e investigator |4 oth | |
| 700 | 1 | |a Andrade, Danieli |e investigator |4 oth | |
| 700 | 1 | |a Fortin, Paul F |e investigator |4 oth | |
| 700 | 1 | |a Ji, Lanlan |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Zhouli |e investigator |4 oth | |
| 700 | 1 | |a Zuily, Stephane |e investigator |4 oth | |
| 700 | 1 | |a Wahl, Denis |e investigator |4 oth | |
| 700 | 1 | |a Nalli, Cecilia |e investigator |4 oth | |
| 700 | 1 | |a Andreoli, Laura |e investigator |4 oth | |
| 700 | 1 | |a Tincani, Angela |e investigator |4 oth | |
| 700 | 1 | |a Chighizola, Cecilia B |e investigator |4 oth | |
| 700 | 1 | |a Gerosa, Maria |e investigator |4 oth | |
| 700 | 1 | |a Meroni, Pierluigi |e investigator |4 oth | |
| 700 | 1 | |a Pengo, Vittorio |e investigator |4 oth | |
| 700 | 1 | |a Radin, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Sciascia, Savino |e investigator |4 oth | |
| 700 | 1 | |a Davis, Stacy |e investigator |4 oth | |
| 700 | 1 | |a Amengual, Olga |e investigator |4 oth | |
| 700 | 1 | |a Atsumi, Tatsuya |e investigator |4 oth | |
| 700 | 1 | |a Uthman, Imad |e investigator |4 oth | |
| 700 | 1 | |a Limper, Maarten |e investigator |4 oth | |
| 700 | 1 | |a de Groot, Philip |e investigator |4 oth | |
| 700 | 1 | |a Ruiz Irastorza, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Ugarte, Amaia |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Pinto, Ignasi |e investigator |4 oth | |
| 700 | 1 | |a Ríos-Garcés, Roberto |e investigator |4 oth | |
| 700 | 1 | |a Cervera, Ricard |e investigator |4 oth | |
| 700 | 1 | |a Rodriguez, Esther |e investigator |4 oth | |
| 700 | 1 | |a Jose Cuadrado, Maria |e investigator |4 oth | |
| 700 | 1 | |a Aguirre Zamorano, Maria Angeles |e investigator |4 oth | |
| 700 | 1 | |a Lopez-Pedrera, Rosario |e investigator |4 oth | |
| 700 | 1 | |a Artim-Esen, Bahar |e investigator |4 oth | |
| 700 | 1 | |a Inanc, Murat |e investigator |4 oth | |
| 700 | 1 | |a Laura Bertolaccini, Maria |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Hannah |e investigator |4 oth | |
| 700 | 1 | |a Efthymiou, Maria |e investigator |4 oth | |
| 700 | 1 | |a Khamashta, Munther |e investigator |4 oth | |
| 700 | 1 | |a Mackie, Ian |e investigator |4 oth | |
| 700 | 1 | |a Sanna, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Knight, Jason S |e investigator |4 oth | |
| 700 | 1 | |a Petri, Michelle |e investigator |4 oth | |
| 700 | 1 | |a Roubey, Robert |e investigator |4 oth | |
| 700 | 1 | |a Ortel, Tom |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Emilio |e investigator |4 oth | |
| 700 | 1 | |a Willis, Rohan |e investigator |4 oth | |
| 700 | 1 | |a Belmont, H Michael |e investigator |4 oth | |
| 700 | 1 | |a Levine, Steven |e investigator |4 oth | |
| 700 | 1 | |a Rand, Jacob |e investigator |4 oth | |
| 700 | 1 | |a Barbhaiya, Medha |e investigator |4 oth | |
| 700 | 1 | |a Erkan, Doruk |e investigator |4 oth | |
| 700 | 1 | |a Salmon, Jane |e investigator |4 oth | |
| 700 | 1 | |a Lockshin, Michael |e investigator |4 oth | |
| 700 | 1 | |a Branch, D Ware |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 48(2021), 4 vom: 22. Apr., Seite 541-547 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2021 |g number:4 |g day:22 |g month:04 |g pages:541-547 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.200513 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2021 |e 4 |b 22 |c 04 |h 541-547 | ||